Five things for pharma marketers to know: Friday, April 14, 2017


1. Rep. Bob Goodlatte (R-VA.) wants stricter regulation of TV ads placed by plaintiff's lawyers, who sue drugmakers on behalf of patients harmed by medicines. Some patients have stopped taking their therapies after seeing the ads. (WSJ)

2. An increasing number of toddlers are receiving prescriptions for antipsychotics. In 2014, about 20,000 prescriptions for drugs like Risperdal and Abilify were given to children two years old or younger, up from 13,000 in 2013. (New York)

3. Neurocrine Biosciences' new drug is expected to cost roughly $60,000 a year. The company, which received FDA approval for the drug this week, will not disclose the price until May. (MarketWatch)  

4. Gay and bisexual men who have been diagnosed with HIV are more likely to promptly begin treatment now than in the past. However, black gay and bisexual men are still less likely than white men to receive antiretroviral therapy. (Reuters)

5. ICMYI: Researchers are working with black pastors to help them recruit patients into clinical trials, as they seek to increase diversity among participants. (Stat)